CompletedPhase 1NCT00003268

Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Studying Acute erythroid leukemia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Principal Investigator: Neal Flomenberg, MD
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Intervention: amifostine trihydrate(drug)
Eligibility: 18 years · All sexes
Timeline: 1998 – 2003

Study locations (1)

Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00003268 on ClinicalTrials.gov

Other trials for Acute erythroid leukemia

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT00658814
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)

See all trials for Acute erythroid leukemia →

← Back to all trials